Biogen Inc (BIIB : NASDAQ)
Common Stock
$225.71
USD
+7.28 (3.33%)
Last updated: 2026-10-09
Follow BIIB
BIIB
Biogen Inc
WealthAwesomePerformance
1 Day
+3.33%
1 Week
+2.65%
1 Month
+7.11%
YTD
+26.93%
Key Statistics
Market Cap
$33.35B
52W High
$230.49
52W Low
$138.00
P/E Ratio
40.09
50 Day MA
$217.05
200 Day MA
$196.44
Beta
0.09
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/9/2026 | $220.62 | $227.20 | $219.23 | $225.71 | $225.71 | 815,000 |
| 10/8/2026 | $220.30 | $223.09 | $215.73 | $218.43 | $218.43 | 1,339,040 |
| 10/7/2026 | $222.93 | $228.00 | $221.40 | $222.15 | $222.15 | 1,298,117 |
| 10/6/2026 | $224.53 | $225.97 | $218.00 | $222.89 | $222.89 | 1,008,100 |
| 10/5/2026 | $220.00 | $223.85 | $218.22 | $223.59 | $223.59 | 951,290 |
| 10/2/2026 | $222.98 | $224.08 | $219.81 | $219.88 | $219.88 | 779,900 |
| 10/1/2026 | $225.50 | $228.31 | $222.50 | $222.82 | $222.82 | 1,755,300 |
| 9/30/2026 | $227.23 | $229.36 | $225.51 | $225.88 | $225.88 | 1,553,300 |
| 9/29/2026 | $227.02 | $229.41 | $224.45 | $227.07 | $227.07 | 1,161,200 |
| 9/28/2026 | $225.87 | $230.49 | $225.51 | $228.69 | $228.69 | 1,332,300 |
Analyst Price Targets
Based on 35 analysts covering BIIB · as of Oct 12, 2026
Wall Street analysts forecast BIIB stock price to rise 6.0% over the next 12 months.
Consensus
Buy4.11 / 5.00
Avg. Target
US$239.18
+6.0% Upside
Previously US$238.18 on Oct 5, 2026
Current Price
US$225.71
Last close
Analyst Breakdown (35 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BIIB's historical volatility
30-Day Vol
25.4%
Annualized
90-Day Vol
35.2%
Annualized
Trend (90d)
+32.5%
Annualized drift
90d Mean
US$253.46
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$234.60 | US$214.89 – US$256.12 |
| 60 trading days | US$243.85 | US$215.39 – US$276.07 |
| 90 trading days | US$253.46 | US$217.72 – US$295.07 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Financials
- Revenue (TTM)
- $10.03B
- EBITDA
- $3.36B
- Profit Margin
- 8.32%
- ROE (TTM)
- 4.58%
- EPS (Diluted)
- 5.63
- Book Value
- 127.61
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About BIIB.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DFLI | Dragonfly Energy Holdings Corp. | $3.72 | +658.88% |
| WFF | WF Holding Limited Ordinary Shares | $12.29 | +499.51% |
| ILLR | Triller Group Inc. Common Stock | $0.08 | +100.97% |
| JZ | Jianzhi Education Technology Group Company Limited American Depositary Shares | $1.28 | +53.48% |
| ZYBT | Zhengye Biotechnology Holding Limited Ordinary Shares | $1.73 | +50.45% |
| VEEA | Veea Inc. | $5.70 | +47.29% |
| QETA | Quetta Acquisition Corporation Common Stock | $16.41 | +41.47% |
| PDSB | PDS Biotechnology Corp | $1.38 | +35.29% |
BIIB.US news timeline
8 articles covering BIIB.US, most recent first
Latest